MCG vs InterQual: What Experienced UM Nurses Need to Know in 2026
Ask ten UM nurses whether MCG or InterQual is the better criteria set, and you will get ten confident answers. Most of them are answering the wrong question. The MCG vs InterQual debate is not really about which tool is superior — it is about what each tool can and cannot decide. And in 2025 and 2026, federal regulators redrew that line in ways every experienced reviewer needs to understand.
If you have worked payer-side or hospital UM for more than a year or two, you already know how to run a case through your criteria set. This post goes a level deeper: how the two products actually differ, where their authority ends under current CMS rules, and what changed this year.
MCG vs InterQual: Two Tools, One Job
Both products exist to answer the same question — does the clinical picture support the requested level of care? — but they come from different companies and different design philosophies.
MCG care guidelines are published by MCG Health, part of the Hearst Health network. The 30th edition, released for 2026, spans inpatient and surgical care, recovery facility care, home care, and behavioral health, and now includes AI-enabled content features alongside the traditional evidence summaries and benchmark data.
InterQual criteria are published by Optum. The InterQual 2026 release marks the product’s 50th year — it has been part of utilization review since the mid-1970s, when severity of illness and intensity of service screening first became standard practice.
Both are updated at least annually. Both are built from peer-reviewed clinical evidence. And both are licensed screening tools — a distinction that matters more than most reviewers realize, as we will see below.
How the Two Criteria Sets Differ in Daily Review
In the MCG vs InterQual comparison, the practical difference shows up in how a review flows.
MCG reads guideline-first. You open the relevant guideline, compare the documented clinical indications against the admission or continued-stay criteria, and check the case against an optimal recovery course and benchmark length-of-stay data. The reviewer navigates the evidence and applies judgment about fit.
InterQual walks you through a structured question sequence. The tool moves stepwise through clinical criteria — severity of illness, intensity of service, or condition-specific questions — and arrives at a recommendation for the level of care. The structure does more of the navigating for you.
Neither approach is objectively better. Experienced reviewers tend to prefer whichever one they trained on. What matters is this: the choice is not yours, and it is not permanent. Your health plan, hospital contract, or state program decides which product you use — and those decisions change. Pennsylvania’s Department of Human Services moved its Medicaid fee-for-service reviews from InterQual to MCG effective July 18, 2025. If your career touches more than one payer, plan on knowing both.
Neither Criteria Set Is the Final Word — CMS Made That Explicit
Here is the part that separates seasoned reviewers from criteria technicians — and the part the MCG vs InterQual debate usually misses entirely. MCG and InterQual screen cases. They do not determine coverage.
For Medicare Advantage, this is now written directly into regulation. Under 42 CFR § 422.101(b), MA plans must follow Traditional Medicare coverage criteria — national coverage determinations, applicable local coverage determinations, and Medicare payment rules, including the two-midnight inpatient admission criteria at 42 CFR § 412.3. A proprietary criteria set cannot override any of that.
The same regulation permits internal coverage criteria only when Medicare coverage criteria are not fully established — and even then, those criteria must be based on current, widely used evidence and made publicly accessible, with the evidence summarized and the rationale explained. “The guideline wasn’t met” is never, by itself, a compliant basis for an adverse Medicare Advantage determination.
Why does this matter to a UM nurse? Because it defines your escalation path. When documentation does not meet criteria, your job is to route the case to physician-level secondary review — not to treat the screening result as a decision. That has always been good practice. Under current MA rules, it is a compliance requirement.
What Changed in 2025 and 2026
Three developments this cycle directly affect how criteria-based review works.
Approved admissions became harder to unwind. In the Contract Year 2026 Medicare Advantage final rule (finalized April 4, 2025), CMS restricted plans from reopening an approved inpatient admission except for obvious error or fraud. The same rule clarified that decisions made concurrent with an enrollee’s care are organization determinations — which means they carry appeal rights. If your workflow includes concurrent review, those determinations now sit squarely inside the appeals framework.
AI oversight tightened everywhere except where you might expect. CMS proposed — but did not finalize — artificial intelligence guardrails in the CY2026 rule. Meanwhile, a February 2026 peer-reviewed analysis in npj Digital Medicine documented what happens when algorithmic tools drive coverage decisions: post-acute care denial rates that more than doubled at one national plan, and appeal reversal rates above 80% for one widely reported predictive tool. The authors’ core point echoes CMS’s own requirement — determinations must rest on the individual patient’s medical history, the physician’s recommendations, and the clinical notes, not on patterns from an aggregate dataset.
Prior authorization arrived in Original Medicare. The CMS Innovation Center’s WISeR Model launched January 1, 2026 in six states, testing AI- and machine-learning-assisted review for selected services with limited evidence of clinical benefit. Notably, CMS requires that every payment recommendation under the model be determined by appropriately licensed clinicians. Even in the most technology-forward review program Medicare runs, the licensed human reviewer remains the decision layer.
If you want the full picture of where automated review is heading — and what it means for your role — the earlier MedScholaria post on artificial intelligence in utilization management covers the clinical decision support vs clinical judgment divide in depth. The 3.0 contact hour AI in Utilization Management course turns that into CE credit you can use for RN license renewal.
Working Fluently in Both: Five Habits of Strong Reviewers
Whichever product your organization licenses, the reviewers who survive audits share the same habits.
1. Document the subset and edition, every time. “Meets criteria” is not defensible documentation. “Meets InterQual 2026 Acute Adult, episode day 2” or “supported per MCG 30th edition inpatient guideline” is. Editions change annually — your note should show which one you applied.
2. Separate the clinical question from the benefit question. MCG and InterQual address medical necessity and level of care. They say nothing about whether a service is a covered benefit under the member’s plan. Conflating the two produces the wrong denial reason — and the wrong appeal outcome.
3. Treat “criteria not met” as a referral, not a result. Route the case to the medical director with a clean, criteria-referenced summary. The physician reviewer makes the adverse determination; your documentation makes it defensible.
4. Know the status rules underneath the criteria. For Medicare admissions, the two-midnight benchmark sits above any proprietary guideline. If status determinations are a weak spot, the MedScholaria post on inpatient vs observation status is the place to start.
5. Track the annual updates. Both vendors publish summaries of changes with each release. Fifteen minutes with the change summary in January saves you from applying last year’s thresholds to this year’s cases.
Where This Fits in Your UM Foundation
Criteria fluency is one pillar of a defensible UM practice — alongside medical necessity documentation, compliant communication, and knowing the regulatory floor under every review.
That full foundation is what Getting Started in Utilization Management for RNs covers in 5.0 contact hours — and experienced reviewers use it as often as career changers, because it organizes what you learned on the job into a framework you can defend in an audit. It is included in the UM Mastery Bundle: three courses and 9.0 contact hours for $239 instead of $277 purchased separately. Current pricing holds through September 30, so this is the month to lock it in.
Get the UM Mastery Bundle →
Know a nurse who is still deciding whether UM is the right move? Send them the free UM Career Starter Kit — it is where most MedScholaria readers begin.
Keep Learning This Month — Free MCG Webinar
If you want to hear how criteria developers think about the data behind the guidelines, MCG is hosting a free webinar, Predicting What Comes Next: Using Claims Data to Anticipate Risk, Variation, and Utilization, on September 17, 2026, from 1–2 pm ET (10–11 am PT). Presenters from Milliman’s clinical analytics team will show how claims data reveals practice variation across inpatient, observation, and outpatient settings — directly relevant to the level-of-care decisions UM nurses screen every day. The session offers 1.0 contact hour through MCG’s own CE provider approval.
Frequently Asked Questions
The MCG vs InterQual question has no winner. Both are evidence-based, annually updated screening tools that address the same core question. Your payer, facility, or state program chooses the product — Pennsylvania Medicaid, for example, switched from InterQual to MCG in July 2025. Strong reviewers are fluent in both.
No. Under 42 CFR § 422.101, MA plans must follow Traditional Medicare coverage criteria, including the two-midnight inpatient criteria. Internal or proprietary criteria apply only where Medicare coverage criteria are not fully established, and they must be publicly accessible and evidence-based.
A nurse reviewer can approve a request that meets criteria. When criteria are not met, the case goes to physician-level review — the adverse medical necessity determination is made by a medical director or other appropriate physician reviewer, not by the screening tool or the nurse applying it.
Often not, and that mismatch drives many payer-provider disputes. A hospital may run MCG while the plan runs InterQual, or the reverse. Documenting to the clinical evidence — rather than to one product’s checkboxes — is what makes your review hold up on both sides.
MedScholaria Consulting, Inc. is approved by the California Board of Registered Nursing, CEP #18046. This blog post is educational content only and does not constitute legal, compliance, or clinical advice. Sources current as of September 2026: 42 CFR § 422.101; CMS CY2026 MA Final Rule fact sheet, Apr. 4, 2025; CMS WISeR Model; Raza et al., npj Digital Medicine, Feb. 2026; MCG 30th Edition release; Optum InterQual 2026 release; MCG–Pennsylvania DHS announcement, Aug. 12, 2025.